Pharmaceutical Technology

NOVEMBER 18, 2023

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

Leads 40

Leads 40

Pharmaceutical Technology

NOVEMBER 18, 2023

RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).

Leads 40

Leads Pharmaceutical 40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.

Leads 40

Leads 40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.

40

40

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Pharmaceutical Technology

NOVEMBER 18, 2023

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

Leads 40

Leads 40

Pharmaceutical Technology

NOVEMBER 18, 2023

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

Leads 40

Leads 40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-4157 is a mrna vaccine commercialized by Merck, with a leading Phase II program in Metastatic Melanoma.

Leads 40

Leads 40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept biosimilar is under clinical development by Amgen and currently in Phase III for Macular Edema.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

CMK-389 is under clinical development by Novartis and currently in Phase II for Pulmonary Sarcoidosis.

40

40